<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25478024</article-id><article-id pub-id-type="pmc">4255525</article-id><article-id pub-id-type="publisher-id">s13195-014-0053-6</article-id><article-id pub-id-type="doi">10.1186/s13195-014-0053-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Breitve</surname><given-names>Monica H</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>monica.breitve@helse-fonna.no</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Chwiszczuk</surname><given-names>Luiza J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>luiza.chwiszczuk@helse-fonna.no</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Hynninen</surname><given-names>Minna J</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>minna.hynninen@psykp.uib.no</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Rongve</surname><given-names>Arvid</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I6">6</xref><email>arvid.rongve@helse-fonna.no</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Br&#x000f8;nnick</surname><given-names>Kolbj&#x000f8;rn</given-names></name><xref ref-type="aff" rid="I7">7</xref><xref ref-type="aff" rid="I8">8</xref><email>bronnick@gmail.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Janvin</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>carmen.janvin@gmail.com</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Aarsland</surname><given-names>Dag</given-names></name><xref ref-type="aff" rid="I9">9</xref><xref ref-type="aff" rid="I10">10</xref><email>daarsland@gmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Section of Mental Health Research, Clinic of Psychiatry, Helse-Fonna HF Haugesund Hospital, Haugesund, 5504, Norway</aff><aff id="I2"><label>2</label>Old Age Department, Clinic of Psychiatry, Helse-Fonna HF Haugesund Hospital, Haugesund, 5504, Norway</aff><aff id="I3"><label>3</label>Neurological Department, Clinic of Medicine, Helse-Fonna HF Haugesund Hospital, Haugesund, 5504, Norway</aff><aff id="I4"><label>4</label>Department of Clinical Psychology, University of Bergen, Christies gate 12, Bergen, 5015, Norway</aff><aff id="I5"><label>5</label>NKS Olaviken Hospital for Old Age Psychiatry, Ulriksdal 8, Bergen, 5009, Norway</aff><aff id="I6"><label>6</label>Faculty of Medicine, University of Bergen, Bergen, 5020, Norway</aff><aff id="I7"><label>7</label>TIPS, Regional Centre for Clinical Research in Psychosis, Stavanger University Hospital, Stavanger, 4068, Norway</aff><aff id="I8"><label>8</label>Network for Medical Sciences, Stavanger University Hospital, Stavanger, 4068, Norway</aff><aff id="I9"><label>9</label>Centre for Age Related Medicine, Stavanger University Hospital, Stavanger, 4068, Norway</aff><aff id="I10"><label>10</label>Department NVS, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, Huddinge, 14157, Sweden</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>16</day><month>9</month><year>2014</year></pub-date><volume>6</volume><issue>5</issue><fpage>53</fpage><lpage>53</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Breitve et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Breitve et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/6/5/53"/><abstract><sec><title>Introduction</title><p>The aim of this review was to investigate whether there is a faster cognitive decline in dementia with Lewy bodies (DLB) than in Alzheimer&#x02019;s disease (AD) over time.</p></sec><sec><title>Methods</title><p>PsycINFO and Medline were searched from 1946 to February 2013. A quality rating from 1 to 15 (best) was applied to the included studies. A quantitative meta-analysis was done on studies with mini mental state examination (MMSE) as the outcome measure.</p></sec><sec><title>Results</title><p>A total of 18 studies were included. Of these, six (36%) reported significant differences in the rate of cognitive decline. Three studies reported a faster cognitive decline on MMSE in patients with mixed DLB and AD compared to pure forms, whereas two studies reported a faster decline on delayed recall and recognition in AD and one in DLB on verbal fluency. Mean quality scores for studies that did or did not differ were not significantly different. Six studies reported MMSE scores and were included in the meta-analysis, which showed no significant difference in annual decline on MMSE between DLB (mean 3.4) and AD (mean 3.3).</p></sec><sec><title>Conclusions</title><p>Our findings do not support the hypothesis of a faster rate of cognitive decline in DLB compared to AD. Future studies should apply recent diagnostic criteria, as well as extensive diagnostic evaluation and ideally autopsy diagnosis. Studies with large enough samples, detailed cognitive tests, at least two years follow up and multivariate statistical analysis are also needed.</p></sec></abstract></article-meta></front><body><sec><title>1 Introduction</title><p>Dementia with Lewy bodies (DLB) and Alzheimer&#x02019;s disease (AD) are the two most common subtypes of neurodegenerative dementia, representing 15 to 20% and 65% of all dementia cases, respectively [<xref ref-type="bibr" rid="B1">1</xref>]. DLB is characterized clinically by symptoms such as visual hallucinations, Parkinsonism and fluctuating cognition in addition to cognitive impairment with typically more visuospatial and executive impairment relative to memory impairment [<xref ref-type="bibr" rid="B2">2</xref>]. There is some evidence that DLB patients have more rapidly progressing dementia compared to AD [<xref ref-type="bibr" rid="B3">3</xref>], and more recent studies also reported a more severe course with shorter survival [<xref ref-type="bibr" rid="B4">4</xref>], higher rate of nursing home admissions [<xref ref-type="bibr" rid="B5">5</xref>] and higher costs in DLB as compared to AD [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>An overlap in neuropathology between AD and DLB has been noted [<xref ref-type="bibr" rid="B7">7</xref>]. Parkinson&#x02019;s disease (PD) and DLB also share some clinical and pathological features [<xref ref-type="bibr" rid="B8">8</xref>]. Subgroups with different cognitive profiles have been described in patients with PD [<xref ref-type="bibr" rid="B9">9</xref>], and there is evidence that this differentiation is related to the rate of cognitive decline [<xref ref-type="bibr" rid="B10">10</xref>]. Similar neuropsychologically defined subgroups may exist also in DLB [<xref ref-type="bibr" rid="B8">8</xref>], which could also predict differences in the rate of progression to end-stage dementia. Data supports accelerated disease progression when AD and DLB pathologies are present together [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>To our knowledge, no systematic review has compared rate of cognitive decline in DLB versus AD. We therefore systematically reviewed the literature to find studies assessing overall cognitive decline in DLB and AD. We specifically noted studies that had investigated the potential differences in cognitive decline in subgroups with DLB and the effect of employing different diagnostic criteria.</p></sec><sec><title>2 Methods</title><p>PsycINFO and Medline were searched in February 2013, using key words listed in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>. References from reviewed articles were also searched for relevant studies. The following inclusion criteria were used: a) paper published in a peer-reviewed journal; b) written in English; c) DLB or mixed AD/DLB compared with AD; d) application of at least one neuropsychological test, and e) at least 6&#x000a0;months follow up. The following exclusion criteria were used: a) drug trials, and b) survival studies with death as the only outcome.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Search history</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th rowspan="2" align="left" valign="top">&#x000a0;</th><th align="left" valign="top"><bold>Medline</bold><hr/></th><th align="left" valign="top"><bold>PsycINFO</bold><hr/></th><th align="left" valign="top">&#x000a0;<hr/></th></tr><tr valign="top"><th align="left" valign="top"><bold>(1946 to February 2013)</bold></th><th align="left" valign="top"><bold>(1806 to February 2013)</bold></th><th align="left" valign="top">&#x000a0;</th></tr></thead><tbody><tr valign="top"><td align="left" valign="top"><bold>Key words</bold><hr/></td><td align="left" valign="top">Alzheimer&#x02019;s disease and Lewy body disease, or Lewy bodies<hr/></td><td align="left" valign="top">Alzheimer&#x02019;s disease and dementia with Lewy bodies<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Key words</bold><hr/></td><td align="left" valign="top">Neuropsychology, or neuropsychological tests, or Cognition, or cognition disorders<hr/></td><td align="left" valign="top">Neuropsychology, or neuropsychological assessment, or neuropsychological assessment, or Cognition, or cognitive impairment, or<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Key words</bold><hr/></td><td align="left" valign="top">Disease progression, or longitudinal studies<hr/></td><td align="left" valign="top">Disease course, or disease prognosis, or longitudinal studies<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Search results</bold><hr/></td><td align="left" valign="top">70<hr/></td><td align="left" valign="top">97<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Included</bold></td><td align="left" valign="top">&#x000a0;</td><td align="left" valign="top">&#x000a0;</td><td align="left" valign="top">18</td></tr></tbody></table></table-wrap><sec><title>2.1 Quality assessment</title><p>Two independent raters rated all studies with a self-designed quality scale and arrived at the same result. The domains, a) number of patients included; b) follow-up time; c) clinical criteria; d) autopsy, and e) neuropsychological tests) were rated on a four-point scale adapted from Aarsland <italic>et al</italic>. (2005) [<xref ref-type="bibr" rid="B12">12</xref>]: 0 (none), 1 (poor), 2 (fair) and 3 (good). See Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>. Studies could be assigned 1 to 15 points.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Quality assessment criteria</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th align="left" valign="top">&#x000a0;<hr/></th><th colspan="4" align="left" valign="top"><bold>Score</bold><hr/></th></tr><tr valign="top"><th align="left" valign="top">&#x000a0;</th><th align="left" valign="top"><bold>3</bold></th><th align="left" valign="top"><bold>2</bold></th><th align="left" valign="top"><bold>1</bold></th><th align="left" valign="top"><bold>0</bold></th></tr></thead><tbody><tr valign="top"><td align="left" valign="top"><bold>Patients at baseline, number</bold><hr/></td><td align="left" valign="top">&#x0003e;151<hr/></td><td align="left" valign="top">101 to 150<hr/></td><td align="left" valign="top">51 to 100<hr/></td><td align="left" valign="top">&#x0003c;50<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Follow-up time, years</bold><hr/></td><td align="left" valign="top">&#x0003e;3 or mean &#x02265;3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">&#x02264;1<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Clinical criteria</bold><hr/></td><td align="left" valign="top">Established criteria for AD&#x02009;+&#x02009;DLB criteria from 2005<hr/></td><td align="left" valign="top">Established criteria for AD&#x02009;+&#x02009;DLB criteria from 1992 or 1996<hr/></td><td align="left" valign="top">Used criteria for one type of dementia<hr/></td><td align="left" valign="top">No criteria used<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Autopsy, % of participants</bold></td><td align="left" valign="top">100</td><td align="left" valign="top">&#x0003e;50</td><td align="left" valign="top">&#x0003e;25</td><td align="left" valign="top">None</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer&#x02019;s disease; DLB, dementia with Lewy bodies; BNT, Boston naming test; CERAD, Consortium to Establish a Registry for Alzheimer&#x02019;s Disease evaluation; DRS, dementia rating scale; ESD, extended scale for dementia; HVLT-R Hopkins verbal learning test-revised; mMMS, modified mini-mental state examination; MMSE, mini mental state examination; MTS, 37 item mental test score.</p></table-wrap-foot></table-wrap></sec><sec><title>2.2 Statistical analysis</title><p>For studies reporting mini mental state examination (MMSE) results, standardized mean difference in annual progression between DLB and AD was calculated as the difference between annual progression between the DLB and AD groups divided by the pooled standard deviation across groups in each included study. The standardized mean differences were combined in a random-effects model to obtain summary estimates of the effect in each study. The overall results from each trial were then combined using a random-effects model to obtain a pooled summary estimate of effect across all trials [<xref ref-type="bibr" rid="B13">13</xref>]. To assess heterogeneity, the <italic>I</italic><sup>2</sup> as proposed by Higgins and colleagues [<xref ref-type="bibr" rid="B14">14</xref>] was chosen, indicating the percentage of total variation across studies due to heterogeneity.</p></sec></sec><sec><title>3 Results</title><p>Of the 18 studies included in this review (see Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>), six (36%) reported a statistically significant difference in cognitive decline over time between AD and DLB (see Table&#x000a0;<xref ref-type="table" rid="T4">4</xref>). Three studies reported a faster cognitive decline on cognitive screening tests in the neuropathologically mixed AD/DLB group [<xref ref-type="bibr" rid="B3">3</xref>],[<xref ref-type="bibr" rid="B15">15</xref>],[<xref ref-type="bibr" rid="B16">16</xref>] compared to those with pure AD or DLB. One study reported a faster decline in DLB than in AD on verbal fluency [<xref ref-type="bibr" rid="B17">17</xref>], and two in AD compared to DLB on memory [<xref ref-type="bibr" rid="B18">18</xref>],[<xref ref-type="bibr" rid="B19">19</xref>]. For a full description of neuropsychological tests used in included studies, see Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Study characteristics and main findings of included studies</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th align="left" valign="top"><bold>Study</bold></th><th align="left" valign="top"><bold>Sample, male/female ratio (m/f), mean age (SD)</bold></th><th align="left" valign="top"><bold>Follow-up period</bold></th><th align="left" valign="top"><bold>Neuropsychological tests</bold></th><th align="left" valign="top"><bold>AD versus DLB comparison</bold></th><th align="left" valign="top"><bold>Test scores, mean (SD)</bold></th></tr></thead><tbody><tr valign="top"><td rowspan="6" align="left" valign="top"><bold>McKeith</bold><bold>
<italic>et al</italic>
</bold><bold>., 1992 [</bold>[<xref ref-type="bibr" rid="B20">20</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 37<hr/></td><td rowspan="6" align="left" valign="top">Baseline and late stage<hr/></td><td rowspan="6" align="left" valign="top">MTS<hr/></td><td rowspan="6" align="left" valign="top">No significant difference<hr/></td><td align="left" valign="top">MTS baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 13/24<hr/></td><td align="left" valign="top">AD 15.9 (1.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 74.7 (0.9)<hr/></td><td align="left" valign="top">SDLT 24.5 (1.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">SDLT 21<hr/></td><td align="left" valign="top">MTS late stage<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 12/9<hr/></td><td align="left" valign="top">AD 9.3 (2.1)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.3 (1.6)<hr/></td><td align="left" valign="top">SDLT 18.2 (2.3)<hr/></td></tr><tr valign="top"><td rowspan="10" align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 1996 [</bold>[<xref ref-type="bibr" rid="B17">17</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 53<hr/></td><td align="left" valign="top">1 y<hr/></td><td align="left" valign="top">CAMCOG<hr/></td><td align="left" valign="top">SDLT faster decline of verbal fluency<hr/></td><td align="left" valign="top">Scores for subtests n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f, n/a<hr/></td><td rowspan="9" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="9" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="9" align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top">Y, n/a<hr/></td><td align="left" valign="top">CAMCOG total, baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">SDLT 7<hr/></td><td align="left" valign="top">AD 42.7 (17.9)<hr/></td></tr><tr valign="top"><td align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">SDLT 47.7 (18.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f, n/a<hr/></td><td rowspan="2" align="left" valign="top">CAMCOG mean annual decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">Y, n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">VaD 14<hr/></td><td align="left" valign="top">AD 13.2 (12.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f, n/a<hr/></td><td rowspan="2" align="left" valign="top">SDLT 27.0 (19.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">Y, n/a<hr/></td></tr><tr valign="top"><td rowspan="8" align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 1998 [</bold>[<xref ref-type="bibr" rid="B21">21</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 30<hr/></td><td rowspan="8" align="left" valign="top">1 y<hr/></td><td rowspan="8" align="left" valign="top">MMSE<hr/></td><td rowspan="8" align="left" valign="top">No significant difference<hr/></td><td align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">m/f 9/21<hr/></td><td align="left" valign="top">AD 13.9<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 14.9<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 81.7<hr/></td><td rowspan="2" align="left" valign="top">MMSE mean annual decline<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">DLB 42<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 4.1<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 19/24<hr/></td><td rowspan="2" align="left" valign="top">DLB 3.9<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.6<hr/></td></tr><tr valign="top"><td rowspan="20" align="left" valign="top"><bold>Olichney</bold><bold>
<italic>et al</italic>
</bold><bold>., 1998 [</bold>[<xref ref-type="bibr" rid="B3">3</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 148<hr/></td><td rowspan="20" align="left" valign="top">Mean 3 y<hr/></td><td rowspan="20" align="left" valign="top">MMSE<hr/></td><td rowspan="20" align="left" valign="top">LBV faster decline<hr/></td><td rowspan="2" align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 80/68<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 74.0 (7.9)<hr/></td><td align="left" valign="top">AD 17.8 (6.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 40<hr/></td><td align="left" valign="top">LBV 18.2 (5.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 25/15<hr/></td><td rowspan="2" align="left" valign="top">MMSE 1 y (n&#x02009;=&#x02009;136/35)<hr/></td></tr><tr valign="top"><td rowspan="15" align="left" valign="top">y 72.4 (6.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 14.3 (7.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 12.5 (7.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">MMSE 2 y (n&#x02009;=&#x02009;93/17)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 12.3 (7.9)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 8.1 (6.3)<hr/></td></tr><tr valign="top"><td align="left" valign="top">MMSE 3 y (n&#x02009;=&#x02009;59/12)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 10.1 (8.4)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 4.5 (6.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">MMSE 4 y (n&#x02009;=&#x02009;35/4)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 9.1 (7.9)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 2.5 (3.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">MMSE mean annual decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 4.1 (3.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 5.8 (4.5)<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top"><bold>Heyman</bold><bold>
<italic>et al</italic>
</bold><bold>., 1999 [</bold>[<xref ref-type="bibr" rid="B18">18</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 74<hr/></td><td rowspan="6" align="left" valign="top">Annual controls<hr/></td><td rowspan="6" align="left" valign="top">CERAD (including CDT, calculation test, serial subtraction, CDR, BNT, MMSE, 10-item word list memory, recall and recognition, constructional praxis, two of the six items of the orientation-memory-concentration test)<hr/></td><td rowspan="6" align="left" valign="top">AD faster decline in delayed recall<hr/></td><td rowspan="6" align="left" valign="top">32% of LBV versus 15% of AD remembered any item on word list recall at last evaluation<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 47/27<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 41% &#x0003e;74 y<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/LBV 27<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 14/13<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 37% &#x0003e;74 y<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top"><bold>Lopez</bold><bold>
<italic>et al</italic>
</bold><bold>., 2000 [</bold>[<xref ref-type="bibr" rid="B22">22</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 98<hr/></td><td rowspan="6" align="left" valign="top">Mean 59&#x000a0;months<hr/></td><td rowspan="6" align="left" valign="top">MMSE<hr/></td><td rowspan="6" align="left" valign="top">No significant difference<hr/></td><td rowspan="2" align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 50/48<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 70.8 (9.4)<hr/></td><td align="left" valign="top">AD 16.0 (6.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 44<hr/></td><td rowspan="3" align="left" valign="top">AD/DLB 16.2 (5.1)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 20/24<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 72.3 (6.0)<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top"><bold>Stern</bold><bold>
<italic>et al</italic>
</bold><bold>., 2001 [</bold>[<xref ref-type="bibr" rid="B23">23</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 32<hr/></td><td rowspan="6" align="left" valign="top">Annual controls, longest 9.9 y<hr/></td><td rowspan="6" align="left" valign="top">mMMSE (including WAIS-R digit span forward, backward, attention, calculation, general knowledge, language, construction), CDR<hr/></td><td rowspan="6" align="left" valign="top">No significant difference<hr/></td><td align="left" valign="top">mMMSE baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 16/16<hr/></td><td align="left" valign="top">AD 36.7 (6.3)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.0 (9.0)<hr/></td><td align="left" valign="top">LBV 37.3 (6.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBV 19<hr/></td><td rowspan="3" align="left" valign="top">mMMSE mean annual decline 3.6 (both groups)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 17/2<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.6 (6.8)<hr/></td></tr><tr valign="top"><td rowspan="19" align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 2001 [</bold>[<xref ref-type="bibr" rid="B24">24</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 101<hr/></td><td rowspan="19" align="left" valign="top">1y<hr/></td><td rowspan="19" align="left" valign="top">MMSE, CAMCOG<hr/></td><td rowspan="19" align="left" valign="top">No significant difference<hr/></td><td align="left" valign="top">MMSE n&#x02009;=&#x02009;203<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 30/71<hr/></td><td align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">probable AD 61&#x000a0;m/f 17/44<hr/></td><td align="left" valign="top">prob AD 17.7 (5.1)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">poss AD 17.2 (5.2)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">y 81.9 (4.8)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">DLB 15.6 (7.0)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">possible AD 40<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">MMSE mean annual decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 13/27<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 79.0 (7.8)<hr/></td><td align="left" valign="top">AD 4.9 (3.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 64<hr/></td><td align="left" valign="top">DLB 4.3 (4.2)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">m/f 26/38<hr/></td><td align="left" valign="top">CAMCOG n&#x02009;=&#x02009;154<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">Baseline 57.5 (18.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 76.6 (7.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">VaD 38<hr/></td><td rowspan="2" align="left" valign="top">CAMCOG mean annual decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 22/16<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top">y 76.8 (7.7)<hr/></td><td align="left" valign="top">Probable AD 15.0 (10.1)<hr/></td></tr><tr valign="top"><td align="left" valign="top">Possible AD 14.4 (9.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 11.9 (12.2)<hr/></td></tr><tr valign="top"><td rowspan="9" align="left" valign="top"><bold>Helmes</bold><bold>
<italic>et al</italic>
</bold><bold>., 2003 [</bold>[<xref ref-type="bibr" rid="B25">25</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 15<hr/></td><td rowspan="9" align="left" valign="top">50&#x000a0;months<hr/></td><td rowspan="9" align="left" valign="top">ESD<hr/></td><td rowspan="9" align="left" valign="top">No significant difference<hr/></td><td rowspan="9" align="left" valign="top">Scores n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 9/6<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 70.3 (7.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 8<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 5/3<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 69.3 (11.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 7<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 5/2<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 69.1 (4.1)<hr/></td></tr><tr valign="top"><td rowspan="8" align="left" valign="top"><bold>Johnson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2005 [</bold>[<xref ref-type="bibr" rid="B26">26</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 66<hr/></td><td align="left" valign="top">Annual controls,<hr/></td><td rowspan="8" align="left" valign="top">WMS (digits forward, backward, logical memory and associate learning), BVRT, word fluency, BNT, WAIS (Digit Symbol and Block Design), TMT A, Crossing Off, CDR<hr/></td><td rowspan="8" align="left" valign="top">No significant difference<hr/></td><td rowspan="8" align="left" valign="top">Follow-up scores n/a. For baseline scores for all tests see article<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 39/27<hr/></td><td rowspan="7" align="left" valign="top">1 to 20 assessments<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 77.0 (8.1)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 57<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 31/26<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 75.2 (9.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 9<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 8/1, age 72.6 (5.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Kraybill</bold><bold>
<italic>et al</italic>
</bold><bold>., 2005 [</bold>[<xref ref-type="bibr" rid="B15">15</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 48<hr/></td><td align="left" valign="top">Annual controls<hr/></td><td align="left" valign="top">MMSE, DRS<hr/></td><td align="left" valign="top">AD/LBP faster decline than AD and LBP<hr/></td><td align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td rowspan="15" align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">m/f 18/30<hr/></td><td rowspan="15" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="15" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="15" align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">AD 20.6 (3.9)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y at onset 77.5<hr/></td><td align="left" valign="top">AD/LBP 20.7 (3.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">(7.34)<hr/></td><td align="left" valign="top">LBP 20.7 (3.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/LBP 65<hr/></td><td align="left" valign="top">MMSE mean annual decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 24/41<hr/></td><td align="left" valign="top">AD 3.5 (0.4)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">y at onset 74.8 (6.6)<hr/></td><td align="left" valign="top">AD/LBP 5.0 (0.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBP 3.4 (0.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBP 22<hr/></td><td align="left" valign="top">DRS baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 16/6<hr/></td><td align="left" valign="top">AD 114.7 (2.1)<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top">y at onset 76.5 (5.3)<hr/></td><td align="left" valign="top">AD/LBP 114.2 (1.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBP 114.2 (2.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DRS mean annual decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 9.6 (1.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/LBP 15.3 (1.9)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LBP 8.8 (1.7)<hr/></td></tr><tr valign="top"><td rowspan="7" align="left" valign="top"><bold>Stavitsky</bold><bold>
<italic>et al</italic>
</bold><bold>., 2006 [</bold>[<xref ref-type="bibr" rid="B19">19</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 55<hr/></td><td rowspan="7" align="left" valign="top">Mean 3 y<hr/></td><td rowspan="7" align="left" valign="top">mMMSE (incl WAIS-R digit Span forward, backward, attention, calculation, general knowledge, language, construction), HVLT-R<hr/></td><td rowspan="7" align="left" valign="top">AD faster decline on recognition.<hr/></td><td align="left" valign="top">mMMSE baseline<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">m/f 21/34<hr/></td><td align="left" valign="top">AD 39.0 (7.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 38.1 (8.3)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.1 (8.3)<hr/></td><td rowspan="4" align="left" valign="top">HVLT-R n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 28<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 19/9<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.5 (7.6)<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top"><bold>Williams</bold><bold>
<italic>et al</italic>
</bold><bold>., 2006 [</bold>[<xref ref-type="bibr" rid="B27">27</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 252<hr/></td><td rowspan="6" align="left" valign="top">&#x0003c; 5 y<hr/></td><td rowspan="6" align="left" valign="top">MMSE, CDR, WMS (mental control, logical memory, digit span forward and backward, associate learning), BVRT, WAIS (information, digit symbol, block design), word fluency, BNT, Crossing off, TMT A<hr/></td><td rowspan="6" align="left" valign="top">No significant difference.<hr/></td><td rowspan="6" align="left" valign="top">Scores n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 95/157<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 77.8 (9.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 63<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 38/25<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 73.5 (8.7)<hr/></td></tr><tr valign="top"><td rowspan="11" align="left" valign="top"><bold>Hamilton</bold><bold>
<italic>et al</italic>
</bold><bold>., 2008 [</bold>[<xref ref-type="bibr" rid="B28">28</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 44<hr/></td><td rowspan="11" align="left" valign="top">2 y<hr/></td><td rowspan="11" align="left" valign="top">DRS, WISC-R (block design), CDT copy, BNT<hr/></td><td rowspan="11" align="left" valign="top">Poor baseline visuospatial skills (block design &#x0003c;20, CDT copy &#x0003c;3) were strongly associated with faster decline in DLB, but not AD.<hr/></td><td align="left" valign="top">DRS baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 20/24<hr/></td><td align="left" valign="top">AD 114.4 (15.4)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 72.0 (5.6)<hr/></td><td align="left" valign="top">DLB 109.5 (11.4)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 22<hr/></td><td rowspan="2" align="left" valign="top">DRS 1 y mean decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 14/8<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top">y 73.4 (6.2)<hr/></td><td align="left" valign="top">AD 7.9 (11.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 17 (24.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DRS 2 y mean decline<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 23.9 (24.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 39.3 (35.1)<hr/></td></tr><tr valign="top"><td align="left" valign="top">Other scores n/a<hr/></td></tr><tr valign="top"><td rowspan="19" align="left" valign="top"><bold>Hanyu</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009 [</bold>[<xref ref-type="bibr" rid="B29">29</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 111<hr/></td><td rowspan="19" align="left" valign="top">5 y<hr/></td><td rowspan="19" align="left" valign="top">MMSE<hr/></td><td rowspan="19" align="left" valign="top">No significant difference<hr/></td><td align="left" valign="top">MMSE<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 37/74<hr/></td><td align="left" valign="top">Baseline n&#x02009;=&#x02009;111/56<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 77.5 (6.2)<hr/></td><td align="left" valign="top">AD 20.3 (3.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 56<hr/></td><td align="left" valign="top">DLB 20.7 (3.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 30/26<hr/></td><td align="left" valign="top">1 y n&#x02009;=&#x02009;111/56<hr/></td></tr><tr valign="top"><td rowspan="14" align="left" valign="top">y 78.1 (5.2)<hr/></td><td align="left" valign="top">AD 19.4 (4.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 20.5 (4.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">2 y n&#x02009;=&#x02009;102/40<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 17.7 (5.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 18.0 (4.8)<hr/></td></tr><tr valign="top"><td align="left" valign="top">3 y n&#x02009;=&#x02009;72/25<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 16.2 (5.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 17.0 (5.3)<hr/></td></tr><tr valign="top"><td align="left" valign="top">4 y n&#x02009;=&#x02009;51/19<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 14.2 (4.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 13.4 (4.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">5 y n&#x02009;=&#x02009;16/5<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 11.4 (5.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 10.6 (4.0)<hr/></td></tr><tr valign="top"><td rowspan="9" align="left" valign="top"><bold>Nelson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009 [</bold>[<xref ref-type="bibr" rid="B16">16</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 107<hr/></td><td rowspan="9" align="left" valign="top">Mean 4 y<hr/></td><td rowspan="9" align="left" valign="top">MMSE<hr/></td><td rowspan="9" align="left" valign="top">AD/DLB had a faster decline than DLB and AD.<hr/></td><td align="left" valign="top">MMSE baseline n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f n/a<hr/></td><td align="left" valign="top">MMSE final<hr/></td></tr><tr valign="top"><td align="left" valign="top">y n/a<hr/></td><td align="left" valign="top">AD 10.7 (8.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 27<hr/></td><td align="left" valign="top">AD/DLB 10.6 (8.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f n/a<hr/></td><td rowspan="5" align="left" valign="top">DLB 15.6 (8.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 9<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f n/a<hr/></td></tr><tr valign="top"><td align="left" valign="top">y n/a<hr/></td></tr><tr valign="top"><td rowspan="13" align="left" valign="top"><bold>Wood</bold><bold>
<italic>et al</italic>
</bold><bold>., 2012</bold>[<xref ref-type="bibr" rid="B30">30</xref>]<hr/></td><td align="left" valign="top">AD 16<hr/></td><td rowspan="13" align="left" valign="top">1 y<hr/></td><td rowspan="13" align="left" valign="top">MMSE, CAMCOG, NEVIP<hr/></td><td rowspan="13" align="left" valign="top">No significant difference.<hr/></td><td align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 12/4<hr/></td><td align="left" valign="top">AD 21.3 (3.2)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 78.9 (6.1)<hr/></td><td align="left" valign="top">DLB 24.5 (3.3)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 10<hr/></td><td rowspan="2" align="left" valign="top">MMSE decline from baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 9/1<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 78.2 (7.4).<hr/></td><td align="left" valign="top">AD 2.1 (3.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">Controls 28<hr/></td><td align="left" valign="top">DLB 1.8 (3.1)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 16/12<hr/></td><td align="left" valign="top">CAMCOG baseline<hr/></td></tr><tr valign="top"><td rowspan="5" align="left" valign="top">y 79.5<hr/></td><td align="left" valign="top">AD 71.4 (9.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 79.1 (12.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">CAMCOG decline from baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 7.4 (10.7)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 4.3 (7.3)<hr/></td></tr><tr valign="top"><td rowspan="14" align="left" valign="top"><bold>Walker</bold><bold>
<italic>et al</italic>
</bold><bold>., 2012</bold>[<xref ref-type="bibr" rid="B31">31</xref>]</td><td align="left" valign="top">AD 100<hr/></td><td rowspan="14" align="left" valign="top">1 y</td><td rowspan="14" align="left" valign="top">MMSE, CAMCOG-R, VOSP, CDR</td><td rowspan="14" align="left" valign="top">No significant difference.</td><td align="left" valign="top">MMSE baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 48/52<hr/></td><td align="left" valign="top">AD 21.5 (4.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">y 74,9<hr/></td><td align="left" valign="top">DLB 21.4 (3.9)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 58<hr/></td><td align="left" valign="top">MMSE follow up (n&#x02009;=&#x02009;81/33)<hr/></td></tr><tr valign="top"><td align="left" valign="top">m/f 37/21<hr/></td><td rowspan="2" align="left" valign="top">AD 19.0 (6.2)<hr/></td></tr><tr valign="top"><td rowspan="9" align="left" valign="top">y 74,2</td></tr><tr valign="top"><td align="left" valign="top">DLB 18.5 (6.0)<hr/></td></tr><tr valign="top"><td align="left" valign="top">CAMCOG-R baseline<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 66.3 (15.6)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 66.0 (13.5)<hr/></td></tr><tr valign="top"><td align="left" valign="top">CAMCOG-R follow up<hr/></td></tr><tr valign="top"><td align="left" valign="top">(n&#x02009;=&#x02009;81/33)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD 59.6 (20.3)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 56.3 (19.7)</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer&#x02019;s disease; DLB, dementia with Lewy bodies; LBP, Lewy body pathology; LBV, Lewy body variant; n/a, not available; SDLT, senile dementia of Lewy body type; VaD, vascular dementia; y, years; BNT, Boston naming test; BVRT, Benton visual retention test; CAMCOG, Cambridge cognitive examination; CAMCOG-R, Cambridge cognitive examination-revised; CDR, clinical dementia rating; CDT, clock drawing test; CERAD, Consortium to Establish a Registry for Alzheimer&#x02019;s Disease evaluation; DRS, dementia rating scale; ESD, extended scale for dementia; HVLT-R, Hopkins verbal learning test-revised; MMSE, mini mental state examination; mMMS, modified mini-mental state examination; MTS, 37-item mental test score; NEVIP, Newcastle visual perception battery; TMT A, trail making test A; VOSP, visual object and space perception battery; WAIS, Wechsler adult intelligence scale; WISC-R, Wechsler intelligence scale for children-revised; WMS, Wechsler memory scale.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Studies reporting differences in cognitive decline</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th align="left" valign="top"><bold>Study</bold></th><th align="left" valign="top"><bold>Cognitive function</bold></th><th align="left" valign="top"><bold>Impairment</bold></th><th align="left" valign="top"><bold>Contrast group</bold></th><th align="left" valign="top"><bold>Test</bold></th></tr></thead><tbody><tr valign="top"><td align="left" valign="top"><bold>Olichney</bold><bold>
<italic>et al</italic>
</bold><bold>., 1998 [</bold>[<xref ref-type="bibr" rid="B3">3</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">Total score<hr/></td><td align="left" valign="top">AD/DLB<hr/></td><td align="left" valign="top">AD<hr/></td><td align="left" valign="top">MMSE<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Kraybill</bold><bold>
<italic>et al</italic>
</bold><bold>l., 2005 [</bold>[<xref ref-type="bibr" rid="B15">15</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">Total score<hr/></td><td align="left" valign="top">AD/DLB<hr/></td><td align="left" valign="top">AD and DLB<hr/></td><td align="left" valign="top">MMSE, DRS<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Nelson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009 [</bold>[<xref ref-type="bibr" rid="B16">16</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">Total score<hr/></td><td align="left" valign="top">AD/DLB<hr/></td><td align="left" valign="top">AD and DLB<hr/></td><td align="left" valign="top">MMSE<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Heyman</bold><bold>
<italic>et al</italic>
</bold><bold>., 1999 [</bold>[<xref ref-type="bibr" rid="B18">18</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">Delayed recall<hr/></td><td align="left" valign="top">AD<hr/></td><td align="left" valign="top">AD/DLB<hr/></td><td align="left" valign="top">CERAD<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Stavitsky</bold><bold>
<italic>et al</italic>
</bold><bold>., 2006 [</bold>[<xref ref-type="bibr" rid="B19">19</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">Recognition<hr/></td><td align="left" valign="top">AD<hr/></td><td align="left" valign="top">DLB<hr/></td><td align="left" valign="top">HVLT-R<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 1996 [</bold>[<xref ref-type="bibr" rid="B17">17</xref>]<bold>]</bold></td><td align="left" valign="top">Verbal fluency</td><td align="left" valign="top">DLB</td><td align="left" valign="top">AD</td><td align="left" valign="top">CAMCOG</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer&#x02019;s disease; AD/DLB, mixed pathology; DLB, dementia with Lewy bodies;</p><p>CAMCOG, Cambridge cognitive examination; CERAD, Consortium to Establish a Registry for Alzheimer&#x02019;s Disease evaluation; DRS, dementia rating scale; HVLT-R, Hopkins verbal learning test-revised; MMSE, mini mental state examination.</p></table-wrap-foot></table-wrap><p>Six studies either reported annual decline in MMSE scores, or included data enabling calculation of annual decline based on reported scores. In AD, mean annual decline was 3.3 (SD 1.7, range 1.8 to 4.9), and in DLB 3.4 (SD 1.4, range 1.8 to 5.8). One study also reported annual decline of 5.0 in AD/DLB (see Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). The random-effects meta-analysis revealed an overall effect-size of &#x02212;0.035 (negative sign indicates faster progression in DLB) (<italic>P</italic>&#x02009;=&#x02009;0.764; 95% CI&#x02009;=&#x02009;0.261, 0.192). <italic>I</italic><sup>2</sup> was 50.3, which is considered to represent moderate heterogeneity [<xref ref-type="bibr" rid="B14">14</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Forrest plot of annual progression of mini-mental state examination scores.</bold> The random-effects meta-analysis revealed an overall effect-size of &#x02212;0.035 (negative sign indicates faster progression in dementia with Lewy bodies (DLB) (<italic>P</italic>&#x02009;=&#x02009;0.764; 95% CI&#x02009;=&#x02009;0.261, 0.192). AD, Alzheimer's disease.</p></caption><graphic xlink:href="s13195-014-0053-6-1"/></fig><sec><title>3.1 Cognitive domains</title><p>Six studies measured memory, and two reported differences in memory over time, both a faster decline in AD. Delayed recall was found to have a faster decline in AD compared to AD/DLB when measured with the Consortium to Establish a Registry for Alzheimer&#x02019;s Disease (CERAD) evaluation, with 15% of patients with AD versus 32% of patients with AD/DLB remembering any item at the last evaluation [<xref ref-type="bibr" rid="B17">17</xref>]. Recognition was found to have a faster decline in AD compared to DLB as measured with Hopkins verbal learning test- revised (HVLT-R) (scores not available) [<xref ref-type="bibr" rid="B19">19</xref>]. Eight studies measuring language and ten studies measuring visuospatial ability reported no differences in rate of decline. Seven studies measured explicit executive functions, and one reported differences over time. In that study, verbal fluency was found to have a more rapid decline in DLB compared to AD, measured with the Cambride cognitive examination (CAMCOG) (subscores not available) [<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>3.2 Subgroups</title><p>Two studies [<xref ref-type="bibr" rid="B28">28</xref>],[<xref ref-type="bibr" rid="B30">30</xref>] divided patients into two groups according to high or low visuospatial functioning. In the first study, DLB patients with a low baseline score (&#x0003c;20) on the Wechsler intelligence scale for children-revised, block design (WISC-R) and impaired clock drawing test (CDT) had a faster decline on the dementia rating scale (DRS), compared to DLB patients with a high baseline score. In the latter study, DLB patients with a low baseline score on the Newcastle visual perception battery (NEVIP) had a faster decline in activities of daily living (ADL) than those with higher score, but no difference on any of the cognitive tests. There were no differences in the AD groups.</p></sec><sec><title>3.3 Quality assessment</title><p>The mean quality score for all the included studies was 9.4 points (SD 2.5, range 5 to 14) (see Table&#x000a0;<xref ref-type="table" rid="T5">5</xref>). Only two studies were rated fair or good on all quality measures [<xref ref-type="bibr" rid="B26">26</xref>],[<xref ref-type="bibr" rid="B27">27</xref>]. Three studies were rated poor on one variable, but fair and good on the others [<xref ref-type="bibr" rid="B15">15</xref>],[<xref ref-type="bibr" rid="B16">16</xref>],[<xref ref-type="bibr" rid="B22">22</xref>]. Mean quality scores for studies that found any differences in cognitive decline was 9.8 points (SD 2.4, range 5 to 11) compared to 9.3 points (SD 2.6, range 5 to 14) in the group with no differences (<italic>P</italic>&#x02009;=&#x02009;0.335).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Quality assessment results</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th align="left" valign="top"><bold>Study</bold></th><th align="left" valign="top"><bold>Sum</bold></th><th align="left" valign="top"><bold>Patients</bold></th><th align="left" valign="top"><bold>Neuropsychological tests</bold></th><th align="left" valign="top"><bold>Time</bold></th><th align="left" valign="top"><bold>Autopsy</bold></th><th align="left" valign="top"><bold>Clinical criteria</bold></th></tr></thead><tbody><tr valign="top"><td align="left" valign="top"><bold>Williams</bold><bold>
<italic>et al</italic>
</bold><bold>., 2006</bold><bold> [</bold>[<xref ref-type="bibr" rid="B27">27</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">14<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Johnson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2005</bold><bold> [</bold>[<xref ref-type="bibr" rid="B26">26</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">13<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Heyman</bold><bold>
<italic>et al</italic>
</bold><bold>., 1999</bold><bold> [</bold>[<xref ref-type="bibr" rid="B18">18</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">11<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Lopez</bold><bold>
<italic>et al</italic>
</bold><bold>., 2000</bold><bold> [</bold>[<xref ref-type="bibr" rid="B22">22</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">11<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Kraybill</bold><bold>
<italic>et al</italic>
</bold><bold>., 2005</bold><bold> [</bold>[<xref ref-type="bibr" rid="B15">15</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">11<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Olichney</bold><bold>
<italic>et al</italic>
</bold><bold>., 1998</bold><bold> [</bold>[<xref ref-type="bibr" rid="B3">3</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">11<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Nelson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009</bold><bold> [</bold>[<xref ref-type="bibr" rid="B16">16</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">11<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Stern</bold><bold>
<italic>et al</italic>
</bold><bold>., 2001</bold><bold> [</bold>[<xref ref-type="bibr" rid="B23">23</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">10<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Stavitsky</bold><bold>
<italic>et al</italic>
</bold><bold>., 2006</bold><bold> [</bold>[<xref ref-type="bibr" rid="B19">19</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">10<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Hamilton</bold><bold>
<italic>et al</italic>
</bold><bold>., 2008</bold><bold> [</bold>[<xref ref-type="bibr" rid="B28">28</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">10<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Helmes</bold><bold>
<italic>et al</italic>
</bold><bold>., 2003</bold><bold> [</bold>[<xref ref-type="bibr" rid="B25">25</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">9<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Hanyu</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009</bold><bold> [</bold>[<xref ref-type="bibr" rid="B29">29</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">9<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>McKeith</bold><bold>
<italic>et al</italic>
</bold><bold>., 1992</bold><bold> [</bold>[<xref ref-type="bibr" rid="B20">20</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">8<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">0<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et a</italic>
</bold><bold>l., 2001</bold><bold> [</bold>[<xref ref-type="bibr" rid="B24">24</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">8<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">2<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Walker</bold><bold>
<italic>et al</italic>
</bold><bold>., 2012</bold><bold> [</bold>[<xref ref-type="bibr" rid="B31">31</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">8<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Wood</bold><bold>
<italic>et al</italic>
</bold><bold>., 2012</bold><bold> [</bold>[<xref ref-type="bibr" rid="B30">30</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">6<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">3<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">3<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 1998</bold><bold> [</bold>[<xref ref-type="bibr" rid="B21">21</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">5<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">0<hr/></td><td align="left" valign="top">1<hr/></td><td align="left" valign="top">2<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 1996</bold><bold> [</bold>[<xref ref-type="bibr" rid="B17">17</xref>]<bold>]</bold></td><td align="left" valign="top">5</td><td align="left" valign="top">1</td><td align="left" valign="top">2</td><td align="left" valign="top">0</td><td align="left" valign="top">0</td><td align="left" valign="top">2</td></tr></tbody></table></table-wrap></sec><sec><title>3.4 Clinical and neuropathological diagnostic criteria</title><p>There were no systematical differences in clinical or neuropathological criteria between studies that found differences in cognitive decline and those who did not (see Table&#x000a0;<xref ref-type="table" rid="T6">6</xref>). Of 18 included studies, 16 (89%) used National Institute of Neurological and Communication Disorders and Stroke/Alzheimer&#x02019;s Disease and Related Disorders Association (NINCDS/ADRDA) or CERAD clinical criteria for AD and 12 (67%) used DLB consensus criteria, only one of them used the revised criteria from 2005. To diagnose AD neuropathologically, mainly CERAD neuropathological criteria for the diagnosis of AD and neuropathological DLB consensus criteria from 1996 were used. A diagnosis of mixed AD/DLB was made, if in addition to the Alzheimer&#x02019;s pathology the characteristic Lewy bodies were found in subcortical and cortical areas. Eleven studies (61%) used autopsy-confirmed diagnosis on all patients. In three studies (17%), some of the diagnoses were autopsy-confirmed. In four studies (22%) autopsy was not performed. One of the studies used <sup>123</sup>I-FP-CIT-SPECT only as a method of verifying of clinical diagnosis [<xref ref-type="bibr" rid="B31">31</xref>].</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Clinical and neuropathological criteria</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th align="left" valign="top"><bold>Study</bold></th><th align="left" valign="top"><bold>Sample</bold></th><th align="left" valign="top"><bold>Database</bold></th><th align="left" valign="top"><bold>Neuropathological criteria</bold></th><th align="left" valign="top"><bold>Autopsy</bold></th><th align="left" valign="top"><bold>Dementia criteria</bold></th></tr></thead><tbody><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>McKeith</bold><bold>
<italic>et al</italic>
</bold><bold>., 1992</bold><bold> [</bold>[<xref ref-type="bibr" rid="B20">20</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 37<hr/></td><td rowspan="3" align="left" valign="top">Newcastle, UK<hr/></td><td rowspan="2" align="left" valign="top">AD: plaque/tangle quantification, H&#x02009;+&#x02009;E, CFV, Loyez, Palmgren.<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td rowspan="3" align="left" valign="top">DLB: proposed consensus (1992)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">SDLT 21<hr/></td></tr><tr valign="top"><td align="left" valign="top">LB: H&#x02009;+&#x02009;E, pholxine, erythrosin<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 1996</bold><bold> [</bold>[<xref ref-type="bibr" rid="B17">17</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 53<hr/></td><td rowspan="3" align="left" valign="top">West Midlands and Bristol, UK<hr/></td><td rowspan="3" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="3" align="left" valign="top">0<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">SDLT 7<hr/></td><td rowspan="2" align="left" valign="top">DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)<hr/></td></tr><tr valign="top"><td align="left" valign="top">VaD 14<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Ballard et al., 1998</bold><bold> [</bold>[<xref ref-type="bibr" rid="B21">21</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 30<hr/></td><td rowspan="3" align="left" valign="top">Newcastle General Hospital, UK<hr/></td><td rowspan="2" align="left" valign="top">AD: CERAD, plaque &#x02013; Braunmuhl stain, tangle &#x02013; modified Palmgren<hr/></td><td rowspan="3" align="left" valign="top">19<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">DLB 42<hr/></td><td rowspan="2" align="left" valign="top">DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Olichney</bold><bold>
<italic>et a</italic>
</bold><bold>l., 1998</bold><bold> [</bold>[<xref ref-type="bibr" rid="B3">3</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 148<hr/></td><td align="left" valign="top">Cohort from:<hr/></td><td align="left" valign="top">AD: CERAD, ADRC<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984),<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">LBV 40<hr/></td><td align="left" valign="top">Univeristy of California, San Diego Alzheimer&#x02019;s Disease Research Center, USA;<hr/></td><td rowspan="2" align="left" valign="top">LB: ubiquitin, H&#x02009;+&#x02009;E (brainstem, cerebral cortex)<hr/></td><td rowspan="2" align="left" valign="top">DSM-III for dementia<hr/></td></tr><tr valign="top"><td align="left" valign="top">CERAD centers, multinational<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Heyman</bold><bold>
<italic>et al</italic>
</bold><bold>., 1999</bold><bold> [</bold>[<xref ref-type="bibr" rid="B18">18</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 74<hr/></td><td rowspan="2" align="left" valign="top">Subjects with premortem diagnosis of probable and possible AD from 24 centers participating in CERAD, 1986 to 1995, USA<hr/></td><td align="left" valign="top">AD: CERAD<hr/></td><td rowspan="2" align="left" valign="top">All<hr/></td><td rowspan="2" align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/LBV 27<hr/></td><td align="left" valign="top">LB: consensus criteria (1996), modified (brainstem, limbic/transitional and noecortical).<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Lopez</bold><bold>
<italic>et al</italic>
</bold><bold>., 2000</bold><bold> [</bold>[<xref ref-type="bibr" rid="B22">22</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 98<hr/></td><td rowspan="2" align="left" valign="top">University of Pittsburg 1983 to 1998, USA<hr/></td><td align="left" valign="top">AD: CERAD, NIA-RI<hr/></td><td rowspan="2" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 44<hr/></td><td align="left" valign="top">LB: H&#x02009;+&#x02009;E, ubiqutin (SN, neocortex, limbic areas)<hr/></td><td align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td rowspan="6" align="left" valign="top"><bold>Stern</bold><bold>
<italic>et al</italic>
</bold><bold>. 2001</bold><bold> [</bold>[<xref ref-type="bibr" rid="B23">23</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 32<hr/></td><td rowspan="2" align="left" valign="top">From cohort of 236 patients with probable AD<hr/></td><td align="left" valign="top">AD: CERAD<hr/></td><td rowspan="6" align="left" valign="top">All<hr/></td><td rowspan="6" align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td rowspan="5" align="left" valign="top">LBV 19<hr/></td><td rowspan="5" align="left" valign="top">LB: semi quantitative ubiquitin (SN, hippocampus, cingulate gyrus, insula cortex)<hr/></td></tr><tr valign="top"><td align="left" valign="top">Recruited:<hr/></td></tr><tr valign="top"><td align="left" valign="top">Columbia University College, New York, USA<hr/></td></tr><tr valign="top"><td align="left" valign="top">Johns Hopkins University, Baltimore, USA<hr/></td></tr><tr valign="top"><td align="left" valign="top">Massachusetts General Hospital, Boston, USA<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Ballard</bold><bold>
<italic>et al</italic>
</bold><bold>., 2001</bold><bold> [</bold>[<xref ref-type="bibr" rid="B24">24</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 101<hr/></td><td align="left" valign="top">Cohort of 227 patients<hr/></td><td rowspan="2" align="left" valign="top">AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren<hr/></td><td rowspan="3" align="left" valign="top">50<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 64<hr/></td><td rowspan="2" align="left" valign="top">Institute of the Health of the Elderly (IHE), Newcastle, UK<hr/></td><td rowspan="2" align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td align="left" valign="top">VaD 38<hr/></td><td align="left" valign="top">LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Helmes</bold><bold>
<italic>et al</italic>
</bold><bold>., 2003</bold><bold> [</bold>[<xref ref-type="bibr" rid="B25">25</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 15<hr/></td><td rowspan="3" align="left" valign="top">University of Western Ontario Dementia Study, Canada<hr/></td><td rowspan="3" align="left" valign="top">No criteria are referred to. Only referred to LB staining methods (Bielschovsky, anti-ubiquitin, anti-synuclein).<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td rowspan="3" align="left" valign="top">Not specified.<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 8<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 7<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Johnson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2005</bold><bold> [</bold>[<xref ref-type="bibr" rid="B26">26</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 66<hr/></td><td rowspan="3" align="left" valign="top">Washington University, from 1979, USA<hr/></td><td rowspan="2" align="left" valign="top">AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 57<hr/></td><td rowspan="2" align="left" valign="top">DLB: consensus criteria (1996) or McKeith, operational criteria for senile dementia of Lewy body type (1992)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 9<hr/></td><td align="left" valign="top">LB: synuclein<hr/></td></tr><tr valign="top"><td rowspan="4" align="left" valign="top"><bold>Kraybill</bold><bold>
<italic>et al</italic>
</bold><bold>., 2005</bold><bold> [</bold>[<xref ref-type="bibr" rid="B15">15</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 48<hr/></td><td rowspan="4" align="left" valign="top">Cohort from University of Washington/Group Health Cooperative Alzheimer&#x02019;s Disease Patient Registry, USA<hr/></td><td align="left" valign="top">AD: CERAD, Braak stages&#x02009;&#x0003e;&#x02009;IV<hr/></td><td rowspan="4" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/LBP 65<hr/></td><td rowspan="2" align="left" valign="top">LB/AD: AD&#x02009;+&#x02009;synuclein (amygdala, SN)<hr/></td><td rowspan="3" align="left" valign="top">DLB: missing criteria because study was started before the consensus criteria for DLB was established.<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">LBP 22<hr/></td></tr><tr valign="top"><td align="left" valign="top">LB: Braak stages&#x02009;&#x0003c;&#x02009;III, synuclein (amygdala, SN)<hr/></td></tr><tr valign="top"><td rowspan="5" align="left" valign="top"><bold>Stavitsky</bold><bold>
<italic>et a</italic>
</bold><bold>l., 2006</bold><bold> [</bold>[<xref ref-type="bibr" rid="B19">19</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 55<hr/></td><td rowspan="2" align="left" valign="top">Cohort of the Predictors Study, 1997:<hr/></td><td align="left" valign="top">AD: CERAD<hr/></td><td rowspan="5" align="left" valign="top">12<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td rowspan="4" align="left" valign="top">DLB 28<hr/></td><td rowspan="4" align="left" valign="top">LB: semi quantitative ubiquitin (hippocampus, cingulate gyrus, insula cortex)<hr/></td><td rowspan="4" align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td align="left" valign="top">Columbia University<hr/></td></tr><tr valign="top"><td align="left" valign="top">Johns Hopkins University,<hr/></td></tr><tr valign="top"><td align="left" valign="top">Massachusetts General Hospital, USA<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Williams</bold><bold>
<italic>et al</italic>
</bold><bold>., 2006</bold><bold> [</bold>[<xref ref-type="bibr" rid="B27">27</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 252<hr/></td><td rowspan="3" align="left" valign="top">Cohort from Washington University, USA<hr/></td><td rowspan="2" align="left" valign="top">AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">DLB 63<hr/></td><td rowspan="2" align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LB: synuclein<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Hamilton</bold><bold>
<italic>et al</italic>
</bold><bold>., 2008</bold><bold> [</bold>[<xref ref-type="bibr" rid="B28">28</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 44<hr/></td><td rowspan="3" align="left" valign="top">University of California, Alzheimer&#x02019;s disease center San Diego, 1985 to 2002, USA<hr/></td><td rowspan="2" align="left" valign="top">AD: modified Braak staging, NIA-RI (1997) and CERAD (1991)<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: NIA-RI and CERAD (1988)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top">DLB 22<hr/></td><td rowspan="2" align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td align="left" valign="top">LB: H&#x02009;+&#x02009;E, ubiquitin (1996) synuclein (2005)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Hanyu</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009</bold><bold> [</bold>[<xref ref-type="bibr" rid="B29">29</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 111<hr/></td><td rowspan="2" align="left" valign="top">Memory Clinic of Tokyo Medical University, 2000 to 2006, Japan<hr/></td><td rowspan="2" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="2" align="left" valign="top">0<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 56<hr/></td><td align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Nelson</bold><bold>
<italic>et al</italic>
</bold><bold>., 2009</bold><bold> [</bold>[<xref ref-type="bibr" rid="B16">16</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 107<hr/></td><td align="left" valign="top">National Alzheimer&#x02019;s Coordinating Center (NACC) Registry - 31&#x000a0;AD centers in USA,<hr/></td><td align="left" valign="top">AD: NIA-RI<hr/></td><td rowspan="3" align="left" valign="top">All<hr/></td><td align="left" valign="top">AD: CERAD (1988)<hr/></td></tr><tr valign="top"><td align="left" valign="top">AD/DLB 27<hr/></td><td rowspan="2" align="left" valign="top">University of Kentucky Alzheimer&#x02019;s Disease Center, USA<hr/></td><td rowspan="2" align="left" valign="top">LB: Braak staging and CERAD<hr/></td><td rowspan="2" align="left" valign="top">DLB: consensus criteria (1996)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 9<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Wood</bold><bold>
<italic>et a</italic>
</bold><bold>l., 2012</bold><bold> [</bold>[<xref ref-type="bibr" rid="B30">30</xref>]<bold>]</bold><hr/></td><td align="left" valign="top">AD 16<hr/></td><td rowspan="2" align="left" valign="top">Newcastle University, UK<hr/></td><td rowspan="2" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="2" align="left" valign="top">0<hr/></td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 12<hr/></td><td align="left" valign="top">DLB: consensus criteria (2005) or (1996)<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Walker</bold><bold>
<italic>et al</italic>
</bold><bold>. 2012</bold><bold> [</bold>[<xref ref-type="bibr" rid="B31">31</xref>]<bold>]</bold></td><td align="left" valign="top">AD 100<hr/></td><td rowspan="2" align="left" valign="top">40 European sites</td><td rowspan="2" align="left" valign="top"><sup>123</sup>I-FTP-SPECT as verifying method</td><td rowspan="2" align="left" valign="top">0</td><td align="left" valign="top">AD: NINCDS/ADRDA (1984)<hr/></td></tr><tr valign="top"><td align="left" valign="top">DLB 58</td><td align="left" valign="top">DLB: consensus criteria (1996)</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer&#x02019;s disease; ADRC, Alzheimer&#x02019;s Disease Research Center; CERAD, The Consortium to Establish a Registry for Alzheimer's Disease; CFV, creasyl fast violet; DLB, dementia with Lewy bodies; H&#x02009;+&#x02009;E, hematoxylin and eosin staining; I-FTP-SPECT, ioflupane single-photon emission computed tomography; LB Lewy body; LBV, Lewy body variant; LBP, Lewy body pathology; NIA-RI, National Institute on Aging-Reagan; NINCDS/ADRDA, National Institute of Neurological and Communication Disorders and Stroke/Alzheimer&#x02019;s Disease and Related Disorders Association; SDLT, senile dementia of Lewy body type; SN, substantia nigra.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>4 Discussion</title><p>In the 18 studies included in this review, no consistent faster rate of decline in DLB as compared to AD on cognitive screening tests was found. When combining studies that used MMSE, the most frequently used scale, a meta-analysis revealed no difference in the annual rate of cognitive decline. There were mixed findings on decline in specific cognitive domains. Two of six studies of memory found a more rapid decline in AD. Only one of seven studies of executive function found a more rapid decline in DLB, and differences in visuospatial or language tests were not found. The hypothesis of a more rapid cognitive decline in autopsied patients with both AD and DLB pathology was supported in three studies. However, findings were inconsistent and other studies did not find differences.</p><p>Differences in methods such as selection criteria, design, neuropsychological tests, dementia severity, diagnostic procedures and criteria can explain the diverse findings and lack of firm conclusions. However, quality assessment did not reveal any systematic differences between studies with high or low quality scores. There were large differences in sample sizes (n&#x02009;=&#x02009;28 to 315), and the studies that could not be included in the meta-analysis or used other tests than MMSE, thus, may have had varying statistical power to detect significant differences between groups. To be able to compare the overall results and draw some general conclusions it would have been ideal that uniform diagnostic criteria had been used in all the studies. Some of the studies initially included patients with a clinical diagnosis of AD only, where analyses were based on autopsy diagnosis which included both AD and DLB.</p><p>A common weakness in the included studies was the choice of neuropsychological measures. When studying cognitive decline over time, cognitive tests that are designed for a specific cognitive domain are required. Screening tests or batteries that use a total score only, often designed for purposes other than research are less suitable. In this review, the MMSE was the most used test, either alone, or in combination with others. The MMSE may not be an optimal measure, especially when using only the total score and not separate subscores for different cognitive domains, as AD and DLB have different cognitive profiles at onset [<xref ref-type="bibr" rid="B32">32</xref>]. This difference in cognitive profile leads to difficulties in choosing an optimal cognitive screening instrument to compare AD and DLB. The MMSE is heavily based on memory and language and is thus more sensitive to changes in AD than in DLB [<xref ref-type="bibr" rid="B33">33</xref>]. DLB is associated with a more severe visuospatial deficit than AD [<xref ref-type="bibr" rid="B32">32</xref>],[<xref ref-type="bibr" rid="B34">34</xref>], but only 1 of 30 points on the MMSE comes from a measure of visuospatial functioning. MMSE may also be less than optimal because of the ceiling and floor effect [<xref ref-type="bibr" rid="B35">35</xref>], which refers to a test being too easy or too difficult to discriminate below or above a certain point, which is a common problem when testing people with dementia. In one of the reviewed studies the children&#x02019;s version of the Wechsler intelligence scale was used to avoid this. The test then lacks age adjusted norms, but it gains a wider range in scores, and therefore can monitor the cognitive decline over a longer period of time. Studies differed also with regard to the time period of observation, from 1 to 20&#x000a0;years. In studies with short follow-up periods, the MMSE may not be a reliable measure, as Clark, Sheppard, Fillenbaum <italic>et al</italic>. (1999) [<xref ref-type="bibr" rid="B36">36</xref>] have argued that MMSE registrations need to be separated by at least three years in order to be a reliable measure of cognitive decline in AD.</p><p>Only few studies investigated, or reported, subgroups with different cognitive profiles in DLB. It could be due to a low number of cases in several studies, and subsequent low statistical power. People die from dementia or reach an endpoint where they are not capable of performing cognitive tests, and therefore in several studies there was a lower number of patients towards the end of the study. This is challenging when performing statistical analysis. Our search did not cover the issue of subgroups with different cognitive profiles thoroughly, as we only included studies comparing DLB with AD, and not studies describing cognitive decline in DLB and potential subgroups alone. However, there are some data that support the hypothesis that there are subgroups in DLB with different cognitive profiles, and subgroups with poor initial visuospatial function may have a more rapid decline than DLB with good visuospatial function [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Due to overlapping symptoms, it can be difficult to determine the correct diagnosis ante mortem between the pure form of AD, mixed AD/DLB and the pure form of DLB. Because clinical criteria cannot distinguish with certainty the individual pathology, the gold standard for validating the clinical assessment is neuropathological diagnosis. Clinical criteria may have a low sensitivity in particular for DLB, which could have been a source of bias in studies that did not include a neuropathological validation of the diagnosis. However, dementia is a clinical diagnosis and both AD and DLB pathology can be found also in cognitively normal elderly subjects. In one study with autopsy, 50% of cases with widespread &#x003b1;-synucleinopathy did not show any clinical signs of dementia [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>In most studies with autopsy, consensus neuropathological criteria were used. Even though not all included studies used consistent and the same neuropathological methods and criteria, and many also used varying combinations, use of post-mortem verification at least increases the validity of the clinical diagnosis.</p><p>It is also important to mention that the sensitivity for detecting Lewy bodies has increased with anti-ubiquitin immunostaining, where tau-positive samples indicate Alzheimer&#x02019;s pathology. Anti-&#x003b1;-synuclein immunostaining has been incorporated in the assessment, which is most sensitive for Lewy body pathology [<xref ref-type="bibr" rid="B2">2</xref>]. Thus, the neuropathological identification of cases may have been less accurate before the new methods were established, and more reliable staging strategies have been developed [<xref ref-type="bibr" rid="B38">38</xref>].</p><p>A complicating issue is the frequent occurrence of mixed pathology [<xref ref-type="bibr" rid="B39">39</xref>], and to underline the complexity of dementia and its pathology, at least four distinct pathological phenotypes have been identified between AD and DLB [<xref ref-type="bibr" rid="B40">40</xref>]. According to Schneider <italic>et al</italic>. (2012) [<xref ref-type="bibr" rid="B7">7</xref>], the locus of neuropathology is associated with a faster decline in cognition. A neocortical type of Lewy body pathology is associated with increased odds of dementia and a faster decline in episodic, semantic and working memory. The limbic-type is more associated with more rapid decline in visuospatial function. Olichney <italic>et al</italic>. (1998) [<xref ref-type="bibr" rid="B3">3</xref>], concluded that patients with Lewy body variant decline faster than patients with Alzheimer&#x02019;s disease. This statement has often been used with reference to rapid progression in DLB, but it actually refers to an AD variant with Lewy body pathology, not to pure DLB. It should be emphasized that it is still uncertain whether AD and DLB are two independent pathologies that may coexist, or the pathologies are related, or one of them is a consequence of the other.</p></sec><sec><title>5 Conclusion</title><p>Only 6 of the 18 included studies in this review found some differences in cognitive decline between DLB and AD over time, and only one of them found a faster decline in DLB. It is difficult to draw firm conclusions based on available studies, since the results are contradictory. Future studies will need to apply recent diagnostic criteria, as well as extensive diagnostic evaluation and autopsy to confirm the diagnosis. Studies with large enough samples, adapted cognitive tests, more than one year of follow up and multivariate statistical analysis are also needed. Inclusion of mild cognitive impairment patients, with subclinical manifestations and an increased risk of developing DLB (for example, who present rapid eye-movement (REM) sleep behavior disorder) could also strengthen the studies. Our final conclusion is that the studies in this review support neither the hypothesis of a faster cognitive decline in DLB, nor in AD.</p></sec><sec><title>Abbreviations</title><p>AD: Alzheimer&#x02019;s disease</p><p>ADL: activities of daily living</p><p>CAMCOG: Cambride cognitive examination</p><p>CDT: clock drawing test</p><p>CERAD: Consortium to Establish a Registry for Alzheimer&#x02019;s Disease evaluation</p><p>DLB: dementia with Lewy bodies</p><p>DRS: dementia rating scale</p><p>HVLT-R: Hopkins verbal learning test-revised</p><p>MMSE: mini mental state examination</p><p>NEVIP: Newcastle visual perception battery</p><p>NINCDS/ADRDA: National Institute of Neurological and Communication Disorders and Stroke/Alzheimer&#x02019;s Disease and Related Disorders Association</p><p>SPECT: ioflupane single-photon emission computed tomotgraphy</p><p>WISC-R: Wechsler intelligence scale for children-revised</p></sec><sec><title>Competing interests</title><p>Dag Aarsland has received research support and honoraria from H Lundbeck, Novartis Pharmaceuticals and GE Health. None of the other authors have competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MHB and LJC have made the conception and design, data acquisition, analysis and interpretation of data, and drafted the manuscript. AR, MJH, CJ, KB and DA have contributed to the analysis and interpretation of data, and revised the manuscript critically for important intellectual content. KB also performed the meta-analysis. All authors have read and approved the final version of the manuscript.</p></sec></body><back><sec><title>Acknowledgement</title><p>We want to thank the librarian in Helse Fonna, Tonje Velde, for helping us with the systematic literature search.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Piepenstock Nore</surname><given-names>S</given-names></name><name><surname>Skogseth</surname><given-names>R</given-names></name><name><surname>Skulstad</surname><given-names>S</given-names></name><name><surname>Ehrt</surname><given-names>U</given-names></name><name><surname>Hoprekstad</surname><given-names>D</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><article-title>Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria</article-title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>26</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1159/000165917</pub-id><pub-id pub-id-type="pmid">18974647</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>McKeith</surname><given-names>IGI</given-names></name><name><surname>Dickson</surname><given-names>DWD</given-names></name><name><surname>Lowe</surname><given-names>JJ</given-names></name><name><surname>Emre</surname><given-names>MM</given-names></name><name><surname>O. apos Brien</surname><given-names>JTJ</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Cummings</surname><given-names>JJ</given-names></name><name><surname>Duda</surname><given-names>JEJ</given-names></name><name><surname>Lippa</surname><given-names>CC</given-names></name><name><surname>Perry</surname><given-names>EKE</given-names></name><name><surname>Aarsland</surname><given-names>DD</given-names></name><name><surname>Arai</surname><given-names>HH</given-names></name><name><surname>Ballard</surname><given-names>CGC</given-names></name><name><surname>Boeve</surname><given-names>BB</given-names></name><name><surname>Burn</surname><given-names>DJD</given-names></name><name><surname>Costa</surname><given-names>DD</given-names></name><name><surname>Del Ser</surname><given-names>T</given-names></name><name><surname>Dubois</surname><given-names>BB</given-names></name><name><surname>Galasko</surname><given-names>DD</given-names></name><name><surname>Gauthier</surname><given-names>SS</given-names></name><name><surname>Goetz</surname><given-names>CGC</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>EE</given-names></name><name><surname>Halliday</surname><given-names>GG</given-names></name><name><surname>Hansen</surname><given-names>LAL</given-names></name><name><surname>Hardy</surname><given-names>JJ</given-names></name><name><surname>Iwatsubo</surname><given-names>TT</given-names></name><name><surname>Kalaria</surname><given-names>RNR</given-names></name><name><surname>Kaufer</surname><given-names>DD</given-names></name><name><surname>Kenny</surname><given-names>RAR</given-names></name><name><surname>Korczyn</surname><given-names>AA</given-names></name><etal/><article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000187889.17253.b1</pub-id><pub-id pub-id-type="pmid">16237129</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Olichney</surname><given-names>JM</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Hofstetter</surname><given-names>CR</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><article-title>Cognitive decline is faster in Lewy body variant than in Alzheimer&#x02019;s disease</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1212/WNL.51.2.351</pub-id><pub-id pub-id-type="pmid">9710002</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Oesterhus</surname><given-names>R</given-names></name><name><surname>Soennesyn</surname><given-names>H</given-names></name><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Vossius</surname><given-names>C</given-names></name><article-title>Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer&#x02019;s disease and Lewy body dementia</article-title><source>Dement Geriatr Cogn Disord</source><year>2014</year><volume>8</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1159/000358051</pub-id><pub-id pub-id-type="pmid">24732348</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Vossius</surname><given-names>C</given-names></name><name><surname>Nore</surname><given-names>S</given-names></name><name><surname>Testad</surname><given-names>I</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><article-title>Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer&#x02019;s dementia</article-title><source>Int J Geriat Psychiatry</source><year>2014</year><volume>29</volume><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1002/gps.4015</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Vossius</surname><given-names>C</given-names></name><name><surname>Rongve</surname><given-names>A</given-names></name><name><surname>Testad</surname><given-names>I</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><article-title>The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study</article-title><source>Am J Geriatr Psychiatry</source><year>2014</year><volume>22</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2012.08.014</pub-id><pub-id pub-id-type="pmid">23567428</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Boyle</surname><given-names>PA</given-names></name><name><surname>Leurgans</surname><given-names>SE</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><article-title>Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies</article-title><source>Brain</source><year>2012</year><volume>135</volume><fpage>3005</fpage><lpage>3014</lpage><pub-id pub-id-type="doi">10.1093/brain/aws234</pub-id><pub-id pub-id-type="pmid">23065790</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Lippa</surname><given-names>CF</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Farmer</surname><given-names>JM</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Galvin</surname><given-names>JE</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Gwinn-Hardy</surname><given-names>KA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>VM-Y</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Nussbaum</surname><given-names>RL</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Ravina</surname><given-names>BM</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><etal/><article-title>DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>812</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000256715.13907.d3</pub-id><pub-id pub-id-type="pmid">17353469</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Janvin</surname><given-names>CC</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Hugdahl</surname><given-names>K</given-names></name><article-title>Subtypes of mild cognitive impairment in Parkinson&#x02019;s disease: progression to dementia</article-title><source>Mov Disord</source><year>2006</year><volume>21</volume><fpage>1343</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1002/mds.20974</pub-id><pub-id pub-id-type="pmid">16721732</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Williams-Gray</surname><given-names>CH</given-names></name><name><surname>Foltynie</surname><given-names>T</given-names></name><name><surname>Brayne</surname><given-names>CEG</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><article-title>Evolution of cognitive dysfunction in an incident Parkinson&#x02019;s disease cohort</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>1787</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1093/brain/awm111</pub-id><pub-id pub-id-type="pmid">17535834</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Clinton</surname><given-names>LK</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name><name><surname>Myczek</surname><given-names>K</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name><article-title>Synergistic Interactions between Abeta, tau, and &#x003b1;-synuclein: acceleration of neuropathology and cognitive decline</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>7281</fpage><lpage>7289</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0490-10.2010</pub-id><pub-id pub-id-type="pmid">20505094</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Zaccai</surname><given-names>J</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><article-title>A systematic review of prevalence studies of dementia in Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2005</year><volume>20</volume><fpage>1255</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1002/mds.20527</pub-id><pub-id pub-id-type="pmid">16041803</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="book"><name><surname>Borenstein</surname><given-names>M</given-names></name><name><surname>Hedges</surname><given-names>LV</given-names></name><name><surname>Higgins</surname><given-names>JPT</given-names></name><name><surname>Rothstein</surname><given-names>HR</given-names></name><source>Introduction to Meta-Analysis</source><year>2011</year><publisher-name>Wiley, New Jersey</publisher-name></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kraybill</surname><given-names>ML</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Tsuang</surname><given-names>DW</given-names></name><name><surname>Teri</surname><given-names>L</given-names></name><name><surname>McCormick</surname><given-names>WC</given-names></name><name><surname>Bowen</surname><given-names>JD</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Cherrier</surname><given-names>MM</given-names></name><article-title>Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>2069</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000165987.89198.65</pub-id><pub-id pub-id-type="pmid">15985574</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Kryscio</surname><given-names>RJ</given-names></name><name><surname>Jicha</surname><given-names>GA</given-names></name><name><surname>Abner</surname><given-names>EL</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Xu</surname><given-names>LO</given-names></name><name><surname>Cooper</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name><article-title>Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>1127</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181bacf9e</pub-id><pub-id pub-id-type="pmid">19805729</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Oyebode</surname><given-names>F</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><article-title>Cognitive decline in patients with Alzheimer&#x02019;s disease, vascular dementia and senile dementia of Lewy body type</article-title><source>Age Ageing</source><year>1996</year><volume>25</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1093/ageing/25.3.209</pub-id><pub-id pub-id-type="pmid">8670554</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>Fillenbaum</surname><given-names>GG</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><name><surname>Peterson</surname><given-names>B</given-names></name><name><surname>Pieper</surname><given-names>C</given-names></name><article-title>Comparison of Lewy body variant of Alzheimer&#x02019;s disease with pure Alzheimer&#x02019;s disease: Consortium to Establish a Registry for Alzheimer&#x02019;s Disease, Part XIX</article-title><source>Neurology</source><year>1999</year><volume>52</volume><fpage>1839</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1212/WNL.52.9.1839</pub-id><pub-id pub-id-type="pmid">10371532</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Stavitsky</surname><given-names>K</given-names></name><name><surname>Brickman</surname><given-names>AM</given-names></name><name><surname>Scarmeas</surname><given-names>N</given-names></name><name><surname>Torgan</surname><given-names>RL</given-names></name><name><surname>Tang</surname><given-names>M-X</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><article-title>The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease</article-title><source>Arch Neurol</source><year>2006</year><volume>63</volume><fpage>1450</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1001/archneur.63.10.1450</pub-id><pub-id pub-id-type="pmid">17030662</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Perry</surname><given-names>RH</given-names></name><name><surname>Fairbarin</surname><given-names>AF</given-names></name><name><surname>Jabeen</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><article-title>Operational criteria for senile dementia for Lewy body type (SDLT)</article-title><source>Psychol Med</source><year>1992</year><volume>22</volume><fpage>911</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1017/S0033291700038484</pub-id><pub-id pub-id-type="pmid">1362617</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>J</given-names></name><name><surname>Lowery</surname><given-names>K</given-names></name><name><surname>Ayre</surname><given-names>GA</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Ince</surname><given-names>P</given-names></name><name><surname>Neill</surname><given-names>D</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><article-title>A prospective study of dementia with Lewy Bodies</article-title><source>Age Ageing</source><year>1998</year><volume>27</volume><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1093/ageing/27.5.631</pub-id><pub-id pub-id-type="pmid">12675102</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Wisniewski</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Kaufer</surname><given-names>DI</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><article-title>Predictors of progression in patients with AD and Lewy bodies</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>1774</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.9.1774</pub-id><pub-id pub-id-type="pmid">10802783</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Stern</surname><given-names>Y</given-names></name><name><surname>Jacobs</surname><given-names>D</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Troncoso</surname><given-names>J</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><article-title>An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><fpage>460</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">11255450</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><name><surname>Swann</surname><given-names>A</given-names></name><name><surname>Neill</surname><given-names>D</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><article-title>The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer&#x02019;s disease</article-title><source>Int J Geriatri Psychiatry</source><year>2001</year><volume>16</volume><fpage>499</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/gps.381</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Helmes</surname><given-names>E</given-names></name><name><surname>Bowler</surname><given-names>J</given-names></name><name><surname>Merskey</surname><given-names>H</given-names></name><name><surname>Munoz</surname><given-names>DG</given-names></name><name><surname>Hachinski</surname><given-names>VC</given-names></name><article-title>Rates of cognitive decline in Alzheimer&#x02019;s disease and dementia with Lewy bodies</article-title><source>Dement Geriatr Cogn Disord</source><year>2003</year><volume>15</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1159/000067969</pub-id><pub-id pub-id-type="pmid">12566594</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Galvin</surname><given-names>JE</given-names></name><article-title>Verbal and visuospatial deficits in dementia with Lewy bodies</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1232</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000180964.60708.c2</pub-id><pub-id pub-id-type="pmid">16247050</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>MM</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Galvin</surname><given-names>JE</given-names></name><article-title>Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>1935</fpage><lpage>1941</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000247041.63081.98</pub-id><pub-id pub-id-type="pmid">17159097</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Hamilton</surname><given-names>JM</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Emond</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><article-title>Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies</article-title><source>Neuropsychology</source><year>2008</year><volume>22</volume><fpage>729</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1037/a0012949</pub-id><pub-id pub-id-type="pmid">18999346</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Hanyu</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Hiraro</surname><given-names>K</given-names></name><name><surname>Kanetaka</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><article-title>Differences in clinical course between dementia with Lewy bodies and Alzheimer&#x02019;s disease</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02388.x</pub-id><pub-id pub-id-type="pmid">19146642</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>JS</given-names></name><name><surname>Watson</surname><given-names>R</given-names></name><name><surname>Firbank</surname><given-names>MJ</given-names></name><name><surname>Mosimann</surname><given-names>UP</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><name><surname>Blamire</surname><given-names>AM</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>JT</given-names></name><article-title>Longitudinal testing of visual perception in dementia with Lewy bodies and Alzheimer&#x02019;s disease</article-title><source>Int J Geriat Psychiatry</source><year>2013</year><volume>28</volume><fpage>567</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1002/gps.3860</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>Z</given-names></name><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Rodda</surname><given-names>J</given-names></name><name><surname>Qassem</surname><given-names>T</given-names></name><name><surname>Tatsch</surname><given-names>K</given-names></name><name><surname>Booij</surname><given-names>J</given-names></name><name><surname>Darcourt</surname><given-names>J</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>J</given-names></name><article-title>Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer&#x02019;s disease: a cohort study</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><fpage>e000380</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2011-000380</pub-id><pub-id pub-id-type="pmid">22318660</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Metzler-Baddeley</surname><given-names>C</given-names></name><article-title>A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease with dementia</article-title><source>Cortex</source><year>2007</year><volume>43</volume><fpage>583</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/S0010-9452(08)70489-1</pub-id><pub-id pub-id-type="pmid">17715794</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Pengas</surname><given-names>G</given-names></name><name><surname>Dawson</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>LA</given-names></name><name><surname>Clatworthy</surname><given-names>P</given-names></name><article-title>Self administered cognitive screening test (TYM) for detection of Alzheimer&#x02019;s disease: cross sectional study</article-title><source>BMJ</source><year>2009</year><volume>338</volume><fpage>b2030</fpage><pub-id pub-id-type="doi">10.1136/bmj.b2030</pub-id><pub-id pub-id-type="pmid">19509424</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Yoshizawa</surname><given-names>H</given-names></name><name><surname>Vonsattel</surname><given-names>JPG</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><article-title>Early neuropsychological discriminants for Lewy body disease: an autopsy series</article-title><source>J Neurol Neurosurg Psychiatr</source><year>2013</year><volume>84</volume><fpage>1326</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2012-304381</pub-id><pub-id pub-id-type="pmid">23308020</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Gould</surname><given-names>RL</given-names></name><name><surname>Abramson</surname><given-names>IS</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><article-title>Measuring cognitive change in a cohort of patients with Alzheimer&#x02019;s disease</article-title><source>Stat Med</source><year>2000</year><volume>19</volume><fpage>1421</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(20000615/30)19:11/12&#x0003c;1421::AID-SIM434&#x0003e;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">10844707</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Sheppard</surname><given-names>L</given-names></name><name><surname>Fillenbaum</surname><given-names>GG</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Koss</surname><given-names>E</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><article-title>Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer&#x02019;s Disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>857</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1001/archneur.56.7.857</pub-id><pub-id pub-id-type="pmid">10404988</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Pirttil&#x000e4;</surname><given-names>T</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><article-title>Applicability of current staging/categorization of &#x003b1;-synuclein pathology and their clinical relevance</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1007/s00401-008-0346-6</pub-id><pub-id pub-id-type="pmid">18297293</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Bugiani</surname><given-names>O</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Gentleman</surname><given-names>S</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Kavantzas</surname><given-names>N</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Korkolopoulou</surname><given-names>P</given-names></name><name><surname>Kov&#x000e1;cs</surname><given-names>GG</given-names></name><name><surname>Meyronet</surname><given-names>D</given-names></name><name><surname>Monoranu</surname><given-names>C</given-names></name><name><surname>Parchi</surname><given-names>P</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Patsouris</surname><given-names>E</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Rozemuller</surname><given-names>A</given-names></name><name><surname>Stadelmann-Nessler</surname><given-names>C</given-names></name><name><surname>Streichenberger</surname><given-names>N</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><article-title>Staging/typing of Lewy body related &#x003b1;-synuclein pathology: a study of the BrainNet Europe Consortium</article-title><source>Acta Neuropathol</source><year>2009</year><volume>117</volume><fpage>635</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0523-2</pub-id><pub-id pub-id-type="pmid">19330340</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Bang</surname><given-names>W</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>2197</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000271090.28148.24</pub-id><pub-id pub-id-type="pmid">17568013</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>McCann</surname><given-names>H</given-names></name><name><surname>Stevens</surname><given-names>CH</given-names></name><name><surname>Cartwright</surname><given-names>H</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><article-title>&#x003b1;-Synucleinopathy phenotypes</article-title><source>Parkinsonism Relat Disord</source><year>2014</year><volume>20</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(13)70017-8</pub-id></mixed-citation></ref></ref-list></back></article>